Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0GMWTW
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
bL-M24D1
|
|||||
| Synonyms |
BL-M24D1
Click to Show/Hide
|
|||||
| Organization |
Sichuan Biokin Pharmaceutical (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Antibody Name |
undisclosed
|
Antigen Name |
Undisclosed
|
|||
| Payload Name |
WA-00
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Head and neck cancer |
1 Trials
|
|||||||||||
| Lung cancer |
2 Trials
|
|||||||||||
| Multiple myeloma |
1 Trials
|
|||||||||||
| Unspecific hematological malignancies |
1 Trials
|
|||||||||||
| Unspecific solid tumor |
4 Trials
|